Curaleaf: Canccord Slashes Price Target, Anticipates Headwinds For 2022
Earlier this month, Curaleaf Holdings, Inc. (CSE: CURA reported its fourth quarter and full year 2021 results. The company announced
Read moreEarlier this month, Curaleaf Holdings, Inc. (CSE: CURA reported its fourth quarter and full year 2021 results. The company announced
Read moreOn March 3rd, Curaleaf Holdings, Inc. (CSE: CURA) reported its fourth quarter and full year 2021 results. The company announced
Read moreCuraleaf Holdings, Inc. (CSE: CURA) released on Thursday post the closing bell its Q4 and full-year 2021 financial results. The
Read moreAs if Curaleaf (CSE: CURA) didn’t already have enough problems. US Treasury sanctions against Russian nationals and their businesses have
Read moreOn February 2nd, Stifel-GMP put out their fourth quarter 2021 earnings preview, calling it “The Calm Before the Storm.” They
Read moreOn February 4th, Canaccord Genuity came out with their cannabis fourth quarter 2021 preview. On that note, they lowered almost
Read moreCuraleaf Holdings (CSE: CURA) has completed its previously announced US$211 million acquisition of Bloom Dispensaries. The acquisition significantly expands the
Read moreOn December 28th, Curaleaf Holdings (CSE: CURA) announced that they have entered into a definitive agreement to acquire Bloom Dispensaries for
Read moreOn December 16th, Curaleaf Holdings (CSE: CURA) announced the closing of US$425 million 8% senior secured notes due 2026. Curaleaf
Read moreOne week after announcing its acquisition of a single dispensary in the state of Arizona, Curaleaf Holdings (CSE: CURA) appears
Read more